Patents by Inventor Kari Alitalo

Kari Alitalo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
    Patent number: 6965010
    Abstract: The present invention provides polypeptides that bind cellular receptors for vascular endothelial growth factor polypeptides; polynucleotides encoding such polypeptides; compositions comprising the polypeptides and polynucleotides; and methods and uses involving the foregoing. Some polypeptides of the invention exhibit unique receptor binding profiles compared to known, naturally occurring vascular endothelial growth factors.
    Type: Grant
    Filed: February 26, 2001
    Date of Patent: November 15, 2005
    Assignees: Licentia, Ltd., Ludwig Institute for Cancer Research
    Inventors: Kari Alitalo, Markku Michael Jeltsch
  • Use of VEGF-C to prevent restenosis
    Patent number: 6958147
    Abstract: The present invention provides materials and methods for preventing stenosis or restenosis of a blood vessel using Vascular Endothelial Growth Factor C (VEGF-C) and/or Vascular Endothelial Growth Factor D (VEGF-D) genes or proteins.
    Type: Grant
    Filed: October 26, 1999
    Date of Patent: October 25, 2005
    Assignees: Licentia Ltd, Seppo Yla-Herttuala, Ludwig Institute of Cancer Research
    Inventors: Kari Alitalo, Seppo Ylä-Herttuala, Mikko O. Hiltunen, Markku M. Jeltsch, Marc G. Achen
  • Method for stimulating connective tissue growth or wound healing
    Publication number: 20050209136
    Abstract: PDGF-D, a new member of the PDGFVEGF family of growth factors, as well as the nucleotide sequence encoding it, methods for producing it, antibodies and other antagonists to it, transfected and transformed host cells expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications, including methods for stimulating growth of a connective tissue or healing a wound in a mammal, which methods comprise administering to the mammal an effective amount of PDGF-D polypeptides or polynucleotides encoding the PDGF-D polypeptides.
    Type: Application
    Filed: March 8, 2004
    Publication date: September 22, 2005
    Applicant: Ludwig Institute for Cancer Research
    Inventors: Ulf Eriksson, Marko Uutela, Kari Alitalo
  • Antibodies specific for vascular endothelial growth factor-B and DNA coding therefor
    Publication number: 20050064493
    Abstract: VEGF-B polypeptides from the PDGF family of growth factors having the property of promoting mitosis and proliferation of vascular endothelial cells, DNA sequences encoding these polypeptides, pharmaceutical compositions containing them and antibodies which react with them. The VEGF-B polypeptides are useful in stimulating angiogenesis as well as in diagnostic applications.
    Type: Application
    Filed: September 24, 2004
    Publication date: March 24, 2005
    Applicant: LICENTIA LTD.
    Inventors: Ulf Eriksson, Birgitta Olofsson, Kari Alitalo, Katri Pajusola
  • Use of VEGF-C or VEGF-D in reconstructive surgery
    Publication number: 20050043235
    Abstract: The present invention provides materials and methods for repairing tissue and using vascular endothelial growth factor C (VEGF-C) genes and/or proteins. Methods and materials related to the use of VEGF-C for the reduction of edema and improvement: of skin perfusion is provided. Also provided is are materials and methods for using VEGF-C before, during, and after reconstructive surgery.
    Type: Application
    Filed: June 14, 2004
    Publication date: February 24, 2005
    Inventors: Kari Alitalo, Anne Saaristo, Marika Karkkainen, Tuomas Tammela, Sirpa Asko-Seljavaara, Seppo Yla-Herttuala, Yulong He
  • Heparin binding VEGFR-3 ligands
    Publication number: 20050032697
    Abstract: The present invention is directed to methods and compositions for making and using chimeric polypeptides that comprise a VEGFR-3 ligand and a heparin binding domain. The chimeric molecules of the present invention retain VEGFR-3 binding activity and an enhanced heparin binding activity as compared to native VEGF-C and/or VEGF-D.
    Type: Application
    Filed: June 14, 2004
    Publication date: February 10, 2005
    Inventors: Kari Alitalo, Yulong He, Toumas Tammela
  • VEGF-B and PDGF modulation of stem cells
    Publication number: 20040248796
    Abstract: The present invention provides materials and methods for VEGF-B and PDGF therapy, especially therapy directed at stem cell recruitment, proliferation, and/or differentiation.
    Type: Application
    Filed: February 4, 2004
    Publication date: December 9, 2004
    Inventors: Kari Alitalo, Ulf Eriksson, Peter Carmeliet, Xuri Li, Desire Collen, Seppo Yla-Herttuala, Petri Salven, Iiro Rajantie
  • Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
    Patent number: 6824777
    Abstract: The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.
    Type: Grant
    Filed: October 9, 1998
    Date of Patent: November 30, 2004
    Assignees: Licentia Ltd., Ludwig Institute for Cancer Research
    Inventors: Kari Alitalo, Arja Kaipainen, Reija Valtola, Lotta Jussila
  • Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
    Patent number: 6818220
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides.
    Type: Grant
    Filed: March 24, 2000
    Date of Patent: November 16, 2004
    Assignees: Licentia Ltd., Ludwig Institute for Cancer Research
    Inventors: Kari Alitalo, Vladimir Joukov
  • VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
    Publication number: 20040214766
    Abstract: The present invention relates to VEGF-C or VEGF-D materials and methods for promoting growth and differentiation of neural stem cells and materials and methods for administering said cells to inhibit neuropathology.
    Type: Application
    Filed: September 23, 2003
    Publication date: October 28, 2004
    Inventors: Kari Alitalo, Marika Karkkainen, Paula Haiko, Kirsi Sainio, Kirmo Wartiovaara
  • Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
    Publication number: 20040208879
    Abstract: The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.
    Type: Application
    Filed: February 9, 2004
    Publication date: October 21, 2004
    Inventors: Kari Alitalo, Arja Kaipainen, Reija Valtola, Lotta Jussila
  • In vivo stimulation of angiogenic activity
    Patent number: 6793918
    Abstract: Angiogenesis is stimulated by introducing two replication-deficient adenovirus vectors to the endothelial cells or proximate to the endothelial cells of an organism. The first vector encodes VEGF-B167 or a fragment or conservative substitution thereof, the second vector encodes VEGF-A or VEGF-C, or fragments or conservative substitutions thereof.
    Type: Grant
    Filed: November 1, 2001
    Date of Patent: September 21, 2004
    Assignees: Ludwig Institute for Cancer Research, Licentia, Ltd., Aventis Pharma SA
    Inventors: Berndt Enholm, Didier Branellec, Seppo Ylae-Herttuala, Ralf Pettersson, Erika Bergsten, Ulf Eriksson, Kari Alitalo, Aude Le Roux
  • Vascular endothelial growth factor D(VEGF-D) antibodies and vectors, and methods of use
    Publication number: 20040175730
    Abstract: VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.
    Type: Application
    Filed: November 12, 2003
    Publication date: September 9, 2004
    Applicants: Ludwig Institute for Cancer Research, Helsinki University Licensing Ltd., OY
    Inventors: Marc G. Achen, Andrew F. Wilks, Steven A. Stacker, Kari Alitalo
  • Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
    Publication number: 20040147448
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides.
    Type: Application
    Filed: March 3, 2004
    Publication date: July 29, 2004
    Inventors: Kari Alitalo, Vladimir Joukov
  • Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
    Publication number: 20040147726
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides.
    Type: Application
    Filed: March 3, 2004
    Publication date: July 29, 2004
    Inventors: Kari Alitalo, Vladimir Joukov
  • Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)
    Patent number: 6764820
    Abstract: The present invention provides materials and methods for screening for and treating hereditary lymphedema in human subjects.
    Type: Grant
    Filed: August 16, 1999
    Date of Patent: July 20, 2004
    Assignees: Ludwig Institute for Cancer Research, Licentia, Ltd., University of Pittsburgh-of the Commonwealth System of Higher Education
    Inventors: Robert E. Ferrell, Kari Alitalo, David N. Finegold, Marika Karkkainen
  • Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
    Publication number: 20040120950
    Abstract: The present invention relates to methods for treating an individual exhibiting symptoms of chronic arthridites, as identified by an elevated level of VEGF-C expression at synovial sites, and provides materials and methods for the modulation of VEGF-C/VEGFR-3 ligand-receptor interactions as a treatment for chronic arthridites.
    Type: Application
    Filed: December 20, 2002
    Publication date: June 24, 2004
    Inventors: Kari Alitalo, Karri Paavonen, Yrjo Konttinen
  • Stimulation of lymphatic growth with an FLT4 ligand
    Patent number: 6730658
    Abstract: Provided are methods of stimulating the growth of lymphatic endothelia using an Flt4 ligand.
    Type: Grant
    Filed: August 2, 2000
    Date of Patent: May 4, 2004
    Assignees: Helsinki University Licensing, Ltd., Ludwig Institute for Cancer Research
    Inventors: Kari Alitalo, Vladimir Joukov
  • Screening and therapy for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)
    Publication number: 20040063656
    Abstract: The present invention provides materials and methods for screening for and treating hereditary lymphedema in human subjects.
    Type: Application
    Filed: September 12, 2003
    Publication date: April 1, 2004
    Inventors: Robert E. Ferrell, Kari Alitalo, David N. Finegold, Marika Karkkainen
  • Platelet-derived growth factor D
    Patent number: 6706687
    Abstract: PDGF-D, a new member of the PDGF/VEGF family of growth factors, is described, as well as the nucleotide sequence encoding it, methods for producing it, antibodies and other antagonists to it, transfected and transformed host cells expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.
    Type: Grant
    Filed: November 10, 1999
    Date of Patent: March 16, 2004
    Assignees: Ludwig Institute for Cancer Research, Helsinki University
    Inventors: Ulf Eriksson, Karin Aase, Xuri Lee, Annica Ponten, Marko Uutela, Kari Alitalo, Arne Oestman, Carl-Henrik Heldin